Zpráva o průběhu klinického hodnocení Annual Report MEMMAT Sledované období: 28. listopad 2021 - 26. květen 2022
| Title in English | Report on the progress of the clinical evaluation Annual Report MEMMAT Monitored period: November 28, 2021 - May 26, 2022 |
|---|---|
| Authors | |
| Year of publication | 2022 |
| MU Faculty or unit | |
| web | MEMMAT |
| Description | EudraCT number: 2010-023691-33 The clinical trial interim report MEMMAT - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, and ATRT describes the course of a clinical trial in the observed period and the current status of the trial. The reports include information on document updates, screening, a number of newly enrolled patients, a general overview of patients enrolled so far, a number of prematurely discontinued patients in the Czech Republic, incidence of serious adverse events, identified protocol violations, information on newly identified characteristics on the investigational medicinal product in relation to safety and efficacy, newly adopted measures (e.g., interventions of ethics committees, foreign control authorities, possible restrictive interventions of the contracting authority) and information on performed internal audits or audits by the contracting authority if applicable. |
| Related projects: |